PR95537

HYDERABAD, India and BOSTON, Mass., April 19, 2022 /PRNewswire=KYODO JBN/--

Excelra, a leading global Data and Analytics provider for Life Science

organizations, has announced a strategic majority investment in Anlitiks, a

young and rapidly growing technology company in the value and evidence domain.

The investment reinforces Excelra's push into the Health Economics and

Outcomes Research (HEOR) and Real-World Evidence (RWE) analytics area. This

deal is a testimony to Excelra's commitment to drug discovery and

commercialization by combining deep scientific domain expertize with

cutting-edge technology and analytics solutions.

Anlitiks, headquartered in Boston, is a HEOR and RWE company, founded by

Kannan Rajagopalan, a technology entrepreneur. According to Kannan, Anlitiks'

mission is to help Life Sciences organizations translate real-world data

rapidly into value evidence, using a unique data + platform + service approach.

The engine driving the business is Anlitiks' RapidAnalyzer(TM) (

https://anlitiks.com/the-platform/?utm_source=cision&utm_medium=pr&utm_campaign=anlitiks-pr),

a flexible, data-agnostic platform that captures the entire lifecycle of

HEOR/RWE from hypothesis, data integration, analysis, visualization to a

research report. RapidAnalyzer(TM) changes the competitive landscape by

drastically reducing the time taken to gain valuable insights on large-scale

data from months to just a matter of weeks.

As President and Chief Scientific Officer at Anlitiks, Dr. Krithika (Kitty)

Rajagopalan, an industry veteran and well-published HEOR, RWE, Pricing, and

Market Access executive, helps provide leadership and direction in defining

reimbursable strategies for biopharmaceutical organizations.

Anandbir Brar, Chief Executive Officer at Excelra, mentioned, "Anlitiks has a

unique platform + consulting business model, combining highly skilled and

experienced HEOR experts, and an integrated platform - RapidAnalyzer(TM) that

helps execute large volumes of analytical workflows. Our combined strength

empowers Life Science organizations with accelerated yet informed

decision-making."

Data and Digital transformation have become a strategic imperative for the

Life Sciences industry to break down silos between multi-omics, clinical

trials, and real-world data. The partnership with Anlitiks augments Excelra's

vision to use domain-led data science to empower innovation from discovery to

market.

Kannan Rajagopalan stated, "Our vision is to be a technology-enabled

disruptive force in generating rapid actionable insights for the Life Science

industry using real-world data. Excelra's focus areas dovetail perfectly with

our growth strategy, making it the beginning of an exciting journey."

About Excelra

Excelra's data and analytics solutions empower innovation in life sciences

from discovery to market. The Excelra edge comes from harmonizing heterogeneous

data sets and applying innovative bioinformatics know-how and technologies to

accelerate drug discovery & development with reliable and result-oriented

insights.

For more information, visit: https://www.excelra.com.

About Anlitiks

Anlitiks is a leading healthcare analytics organization dedicated to

translating real-world data into value evidence by employing a unique

data-agnostic platform-service model.

To know more, visit: www.anlitiks.com.

For media inquiries, contact:

Jigesh Shah

Jigesh.shah@excelra.com

Logo: https://mma.prnewswire.com/media/692189/Excelra_Logo.jpg

Logo: https://mma.prnewswire.com/media/1799624/anlitiks_Logo.jpg

Source: Excelra Knowledge Solutions Pvt Ltd